Participated · Equity · Jun 2026

Spot Biosystems is developing an engineered extracellular vesicle (EV) delivery platform designed to encapsulate large nucleic acid cargo and enable repeat, non-viral dosing to skeletal muscle. The company reported a peer-reviewed study in Nature Biomedical Engineering showing EV-delivered full-length dystrophin mRNA produced sustained protein expression and improved muscle function in DMD knockout mice and sustained expression without organ toxicity in non-human primates. Spot has launched an investigator-initiated first-in-human trial at Shanghai Children's Medical Center, where the first two pediatric patients demonstrated respective 1000%+ and 2000%+ increases in dystrophin after one month and functional improvement lasting up to six months after dosing cessation. The platform is positioned to overcome limitations of AAV-based approaches by supporting larger cargo and repeat dosing. Financially, Spot emerged from stealth with $40 million in venture financing from a syndicate including LDV Partners, IDG Capital, Advantech Capital, Tiger Jade Capital, Shanda Ventures, the Stanford StartX fund, and Saltagen Ventures. The company intends to use clinical data from the IIT to inform future regulatory pathways and further clinical development for Duchenne muscular dystrophy.

Led · Series A · Nov 2021

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company developing and commercializing targeted radiopharmaceutical therapies (TRT) against tumor targets. The company is focused on building a pipeline of advanced TRT products aimed at treating solid tumors. It plans to use the Series A proceeds to expand its leadership team, build radiopharmaceutical infrastructure, and secure strategic collaborations. Ablaze has a partnership with RayzeBio that grants it exclusive development and commercial rights to a series of RayzeBio’s products in the greater China region. Founded in 2021 and led by co-founder, President and CEO Dr. Alex Qiao, Ablaze operates out of Shanghai, China and San Diego, CA. The company raised $75M in a Series A financing to advance its clinical and commercialization efforts.

Led · Series B · Jun 2021

OncoNano Medicine is a Southlake, Texas–based medical company that exploits pH as a biomarker to diagnose and treat cancer. Its product portfolio includes solid tumor therapeutics, agents for real-time image-guided surgery, and a platform of product candidates that activate and guide the body’s immune system to target cancer. The company is developing pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors. It also is advancing an internal therapeutic development program, ONM-501, a novel immune-therapeutic formulated with its core delivery technology. OncoNano intends to use the funds to support Phase 3 clinical trials in the U.S. and Europe for pegsitacianine and to accelerate advancement of ONM-501. The company is led by CEO Martin Driscoll. OncoNano Medicine develops products that exploit pH as a biomarker to diagnose and treat cancer, centered on a proprietary pH-activated micelle platform. Its lead candidate, pegsitacianine, is a fluorescent nanoprobe under study as a real-time intraoperative imaging agent for solid tumor resection and is in Phase 2 trials. The company is also advancing ONM-501, a next-generation dual-activation STING agonist immuno-therapeutic, toward first-in-human studies. Proceeds from the recent financing will support initiation of pivotal Phase 3 trials of pegsitacianine in the U.S. and Europe and help accelerate ONM-501 through IND submission and Phase 1a/1b trials. OncoNano says the Series B funds combined with support from the Cancer Prevention & Research Institute of Texas will provide resources to operate for several years and advance pegsitacianine toward commercialization. The company is based in Southlake, Texas. OncoNano’s lead product, ONM-100, uses a pH-sensitive micelle platform that activates a fluorescent tag in the acidic tumor microenvironment to enable intraoperative imaging of solid tumors. ONM-100 is in Phase 2 clinical trials and has received FDA Fast Track designation. During trials the company found ONM-100 can also image and stage metastatic disease, and the company plans to expand its application to identify metastatic deposits in the peritoneum, lymph nodes and pleural surfaces. OncoNano also advances ONM-500, a candidate that leverages the same micelle technology to deliver antigens and activate innate immunity for HPV-associated cancers. The company has received multiple CPRIT awards to support development of these programs. OncoNano is based in Southlake, Texas. OncoNano Medicine is developing a platform of pH-sensitive micelles that detect diseased tissue and enable targeted imaging and therapeutic applications. Its lead product, ONM-100, is an intravenously administered intraoperative imaging agent that detects tumors and metastatic lymph nodes. The company completed a Phase 1 trial of ONM-100 that reported a 100% imaging response in patients and has an IND accepted by the FDA; ONM-100 is entering a Phase 2 clinical trial and a separate application received Fast Track designation. OncoNano is applying the same micelle platform to therapeutic candidates, including a T-cell activator that targets lymph nodes and dendritic cells, and exploring cancer vaccine applications. Proceeds from the recent financing are intended to fund the imaging clinical trials and support expansion into therapeutic programs. OncoNano Medicine develops a new class of pH-activated compounds that digitalize and exploit pH variability to detect and treat diseased tissue. Its lead program, ONM-100, is an injectable imaging agent designed to target acidic pH within tumors to help surgeons distinguish cancer from healthy tissue in real time during surgery. ONM-100 is intended to fit seamlessly with current surgical practices for intraoperative assessment, cancer staging, and post-surgery evaluation of lymph nodes and tumor margins. The company announced a $11.7 million Series A financing to support continued clinical development of the platform and to expand applications across therapeutics and imaging agents. This Series A supplements a prior $6 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The platform’s technology was invented at the University of Texas Southwestern Medical Center, and the inventors remain engaged on the company’s scientific advisory board. OncoNano also appointed five established industry leaders to its board to support its clinical and commercial progress.

Participated · Series D · Sep 2020

InventisBio is a Shanghai, China–based clinical-stage biotech focused on discovering and developing proprietary small-molecule drugs for cancer and metabolic diseases. Led by Dr. Yaolin Wang (Chairman and CEO), the company currently has three drug candidates in mid- to late-stage clinical development and one new candidate that recently entered a global Phase I study. Its lead programs include D-0502, an oral selective estrogen receptor degrader (SERD) and antagonist for hormone receptor–positive breast cancer, and BPI-D0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. BPI-D0316's China rights have been out-licensed to Betta Pharma and the product is undergoing registration trials for first- and second-line treatment of EGFR-mutated non-small cell lung cancer. The company is also developing D-0120 for gout. Plans include advancing current programs through Phase II studies in China and the United States and expanding the product pipeline and team. InventisBio is a clinical-stage biotech led by Dr. Yaolin Wang focused on discovering and developing novel therapeutics against cancer and metabolic diseases. The company has three drug candidates in clinical development for breast cancer, lung cancer and gout. It licensed China rights to its third-generation EGFR‑T790M inhibitor D‑0316 to Betta Pharma in December 2018 and is co-developing D‑0316 in a phase 2 trial for non-small cell lung cancer. InventisBio intends to use the new funds to accelerate development of its clinical candidates into phase 2 trials and to advance other drug candidates into the clinic. Prior financings noted in the articles include angel investment from Beautiful Mind Capital, a Series A led by Lilly Asia Venture in 2016 and a Series B led by OrbiMed Asia with participation from LAV in 2017. InventisBio is a Shanghai-based biotech dedicated to the discovery and development of novel medicines. Its pipeline includes small-molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also developing agents intended to be combined with immune-oncology targeted therapies such as PD-1 antibodies. Three drug candidates were expected to enter Phase 1 clinical trials in the US and China in 2017. InventisBio was co-founded by Chairman and CEO Dr. Yaolin Wang and other scientists with prior experience at Merck and Schering-Plough. Prior financings and the recent Series B provide capital to advance its preclinical and early-clinical programs.

Participated · Series B · May 2019

Alphamab Oncology develops multifunctional biologics for cancer using protein engineering and proprietary platforms, including Bispecific and Mix-mAb platforms and single-domain antibodies. Led by Dr. Ting Xu (Founder, Chairman and CEO), the company is advancing multiple clinical-stage assets. Its pipeline includes KN035 (Envafolimab), a subcutaneous PD-L1 antibody in phase II and phase III trials; KN046, a PD-L1/CTLA-4 bispecific progressing through phase II after phase I trials; KN026, an anti-HER2 bispecific entering phase II in China; and immunomodulator KN019 in phase II. Alphamab has formed partnerships (HEC Research Institute and TOT Biopharm) to develop combination therapies involving KN046. The company plans to use new funds to develop its pipeline, commission a new R&D and manufacturing site, accelerate clinical development of its assets, and prepare for commercial launch of KN035. Financially, Alphamab completed a US$60M Series B in May 2019 following a US$130M Series A in November 2018. Alphamab Oncology is a clinical-stage biopharmaceutical company focused on discovery, development, manufacturing and commercialization of cancer therapeutics. Led by Dr. Xu Ting, the company uses multiple in-house platforms including bispecifics, protein engineering and antibody screening. Its oncology/immunology pipeline includes KN035 (Envafolimab), a subcutaneously administered PD-L1 antibody in pivotal trials in China; KN046, a PD-L1–CTLA-4 bispecific in phase I in Australia with planned phase I/II trials in China and BLA-enabling studies; and KN026, an anti-HER2 bispecific in phase I in China. Alphamab plans to use the financing to advance global clinical development—especially its second-generation immuno-oncology medicine—expand global clinical and commercial teams, and complete construction of its biologics manufacturing facilities. The company completed a Series A financing of more than $100 million to support these objectives.